The Experts below are selected from a list of 11124 Experts worldwide ranked by ideXlab platform

Mark H. Schoenfisch - One of the best experts on this subject based on the ideXlab platform.

  • nitric oxide release part iii measurement and reporting
    Chemical Society Reviews, 2012
    Co-Authors: Peter N. Coneski, Mark H. Schoenfisch
    Abstract:

    Nitric oxide's expansive physiological and regulatory roles have driven the development of therapies for human disease that would benefit from exogenous NO administration. Already a number of therapies utilizing gaseous NO or NO donors capable of storing and delivering NO have been proposed and designed to exploit NO's influence on the Cardiovascular System, Cancer biology, the immune response, and wound healing. As described in Nitric oxide release: Part I. Macromolecular scaffolds and Part II. Therapeutic applications, the preparation of new NO-release strategies/formulations and the study of their therapeutic utility are increasing rapidly. However, comparison of such studies remains difficult due to the diversity of scaffolds, NO measurement strategies, and reporting methods employed across disciplines. This tutorial review highlights useful analytical techniques for the detection and measurement of NO. We also stress the importance of reporting NO delivery characteristics to allow appropriate comparison of NO between studies as a function of material and intended application.

Peter N. Coneski - One of the best experts on this subject based on the ideXlab platform.

  • nitric oxide release part iii measurement and reporting
    Chemical Society Reviews, 2012
    Co-Authors: Peter N. Coneski, Mark H. Schoenfisch
    Abstract:

    Nitric oxide's expansive physiological and regulatory roles have driven the development of therapies for human disease that would benefit from exogenous NO administration. Already a number of therapies utilizing gaseous NO or NO donors capable of storing and delivering NO have been proposed and designed to exploit NO's influence on the Cardiovascular System, Cancer biology, the immune response, and wound healing. As described in Nitric oxide release: Part I. Macromolecular scaffolds and Part II. Therapeutic applications, the preparation of new NO-release strategies/formulations and the study of their therapeutic utility are increasing rapidly. However, comparison of such studies remains difficult due to the diversity of scaffolds, NO measurement strategies, and reporting methods employed across disciplines. This tutorial review highlights useful analytical techniques for the detection and measurement of NO. We also stress the importance of reporting NO delivery characteristics to allow appropriate comparison of NO between studies as a function of material and intended application.

Eun Hee Cho - One of the best experts on this subject based on the ideXlab platform.

  • effect of dpp 4 inhibitors on the Cardiovascular System Cancer and pancreatitis
    The Journal of Korean Diabetes, 2013
    Co-Authors: Eun Hee Cho
    Abstract:

    Recently, dipeptidylpeptidase-4 (DPP-4) inhibitors have been widely used as a second-line therapy for type 2 diabetes because of their glucose-lowering efficacy, weight neutral effects and minimal hypoglycemia. However, there have been concerns regarding the lack of evidence of the long-term consequences of DPP-4 inhibitors on Cardiovascular disease, acute pancreatitis and Cancers; therefore, the effects of DPP-4 inhibitors on these three major diseases are reviewed in this article. A growing body of evidence demonstrates the cardioprotective role of DPP-4 inhibitors in animal and small clinical studies. However, clearly conflicting data regarding the effects of DPP-4 inhibitors on Cancers and pancreatitis have been presented in preclinical and epidemiologic studies. The forthcoming long-term clinical studies on Cardiovascular safety will provide more conclusive answers relating to the safety of DPP-4 inhibitors, including their effects on Cancer and pancreatitis. (J Korean Diabetes 2013;14:138-142)